Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment
Abstract Background Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of underlying Alzheimer’s disease (AD) pathology in mild cognitive impairment (MCI). However, CSF biomarker-based classification often results in conflicting profiles with controversial prognostic value....
Main Authors: | Inês Baldeiras, Isabel Santana, Maria João Leitão, Helena Gens, Rui Pascoal, Miguel Tábuas-Pereira, José Beato-Coelho, Diana Duro, Maria Rosário Almeida, Catarina Resende Oliveira |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-018-0362-2 |
Similar Items
-
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
by: Julie K. Wisch, et al.
Published: (2023-01-01) -
Aβ42 as a Biomarker of Alzheimer’s Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?
by: Silvia Boschi, et al.
Published: (2022-12-01) -
Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
by: Caterina Motta, et al.
Published: (2023-08-01) -
Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer’s disease.
by: Aline eDorey, et al.
Published: (2015-11-01) -
Coumarin derivatives against amyloid-beta 40 – 42 peptide and tau protein
by: Kowalczyk Joanna, et al.
Published: (2022-08-01)